Do your patients challenge you? Do you live up to their expectations? How many steps do you have to climb to be better?
CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis (AS), a multinational study found.
Patients believe that a lab result is a numeric true representation their biology and a pivotal arbiter of wellness, yet physicians often dismiss such results as hanging chads in a meaningless election. Why do patients believe their labs moreso than their doctor?
A recent report from the Mayo Clinic describes a 49 year-old patient with lupus nephritis who presented with new-onset hypertension, edema, arthritis, serositis and leukocytoclastic vasculitis, and who later developed glomerulonephritis and nephrotic syndrome.
A prospective study of 136 people who were CCP+, but who had no clinical evidence of synovitis, examined what factors may predict future development of inflammatory arthritis.
After a mean of 18 mos, 42% were diagnosed with inflammatory arthritis and 49/57 met ACR/EULAR criteria for the diagnosis of rheumatoid arthritis (RA).
What to do when a patient has a latex allergy and you prescribe an injectable biologic (many having latex allergy as a contraintication)?
(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.
In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA). While these guidelines defined the target (LDAS) and manner of assessment (that would include quantification of synovitis), these were largely consensus based.
Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi).
Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders. The opportunity to substantially reduce the cost of biologics through the use of biosimilars poses a significant advantage to patients, practitioners and governments internationally.
A national audit of rheumatoid arthritis (RA) and early inflammatory arthritis patients included 6,354 patients drawn from 143 trusts and health boards in England and Wales. Early arthritis clinics exist in 57% of trusts. The report examined the assessment, referral and early secondary care management of patients presenting with early inflammatory arthritis (EIA).
A systematic review of the literature was done to assess the relationship between immunosuppressive therapy, adult systemic lupus erythematosus (SLE) and the onset of progressive multifocal leukoencephalopathy.
A total of 35 publications met inclusion criteria, and this included four observational studies, two large case series, and 29 case reports describing a total of 35 cases.
A retrospective study of elderly rheumatoid arthritis (RA) patients on Medicare was conducted by a group of researchers from the University of Alabama. They aimed to compare the coronary heart disease risk among RA patients initiating biologic disease-modifying anti-rheumatic drugs of different mechanisms between 2006-1012. (Citation source http://buff.ly/1PJDemH)
The American Society of Bone and Mineral Research (ASBMR) Task Force has issued a guidance report on the use of bisphosphonates (BP) with a focus on the risk vs. benefits of such therapy. (Citation source http://buff.ly/1Nn0CVb)
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.
